SCH 54292

CAS No. 188480-51-5

SCH 54292( SCH54292 )

Catalog No. M12947 CAS No. 188480-51-5

SCH 54292 is a potent Ras-GEF interaction inhibitor with IC50 of 0.7 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 364 In Stock
5MG 288 In Stock
10MG 429 In Stock
25MG 708 In Stock
50MG 977 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SCH 54292
  • Note
    Research use only, not for human use.
  • Brief Description
    SCH 54292 is a potent Ras-GEF interaction inhibitor with IC50 of 0.7 uM.
  • Description
    SCH 54292 is a potent Ras-GEF interaction inhibitor with IC50 of 0.7 uM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SCH54292
  • Pathway
    MAPK/ERK Signaling
  • Target
    Ras
  • Recptor
    Ras
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    188480-51-5
  • Formula Weight
    520.553
  • Molecular Formula
    C24H28N2O9S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C1=CC=C2C=C(C=CC2=C1)OCCN(C3C(C(C(C(O3)CO)O)O)O)S(=O)(=O)C4=CC=C(C=C4)NO
  • Chemical Name
    4-(hydroxyamino)-N-(2-naphthalen-2-yloxyethyl)-N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]benzenesulfonamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Taveras AG, et al. Bioorg Med Chem. 1997 Jan;5(1):125-33. 2. Ganguly AK, et al. Biochemistry. 1998 Nov 10;37(45):15631-7.
molnova catalog
related products
  • BI-3406

    BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 : 6 nM),with anticancer activity.

  • ZCL278

    A potent, cell-permeable Cdc42-specific small-molecule inhibitor (Kd=6.4 uM).

  • 1588-A4

    1588-A4 is an intermediate of ARS-1620 which is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics.